Live Breaking News & Updates on Sino Biological Inc Jan
Stay updated with breaking news from Sino biological inc jan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Despite advancements in treatment, cancer is still a huge public health issue. This white paper from Sino Biological discusses and demonstrates their research tools suited for anti-cancer drug targets and treatments. ....
As SARS-CoV-2 variants continue to emerge, it is becoming more and more necessary to understand how best to respond to said variants. This white paper from Sino Biological discusses their efforts to combat the emergence of these variants. ....
Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research. ....
Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas. ....
Innovation and the Mastery of Core Technologies are the Keys for the Success of Bio-Pharmaceutical Enterprises At the beginning of 2020, when COVID-19 broke out unexpectedly and viciously, top research institutions and enterprises in China responded quickly, and the virus antibody R&D team of Sino Biological Inc. was one of them. After receiving the task, the R&D team from Sino Biological started to invest themselves into this task without any delay and completed the expressions of important target antigen protein S-RBD of SARS-CoV-2 successfully within only 11 days, and developed industrial-grade core antigen protein reagents; also, it supported Wondfo to complete the marketing of the first batch of SARS-CoV-2 diagnostic products on February 22. ....